Skip to main content
Annals of Intensive Care
Figure 1 | Annals of Intensive Care

Figure 1

From: Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)

Figure 1

ARR was 19.7% for IRP A + patients (95% CI 2.2–37.1%) and −8.9% for IRP A − patients (95% CI −22.6 to 4.9%). The SNP-by-treatment interaction P value was 0.018 unadjusted and 0.066 adjusted for matching covariates. The proportion of patients who were IRP A + was 33.7% (140/415) in the replication cohort. The ARR was 21.2% for IRP B + patients (95% CI 3.2–39.2%) and −5% for IRP B − patients (95% CI −18.2 to 8.2%). The SNP-by-treatment interaction P value was 0.04 unadjusted and 0.069 adjusted for matching covariates. The proportion of patients who were IRP B + was 26.1% (107/410) in the replication cohort.

Back to article page